MaaT Pharma
MAAT | PA
Overview
Corporate Details
- ISIN(s):
- FR0012634822 (+1 more)
- LEI:
- 969500CQQB6XUNW6CN97
- Country:
- France
- Address:
- 70 AVENUE TONY GARNIER, 69007 LYON
- Website:
- https://www.maatpharma.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Building a leading microbiome company in oncology MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-14 18:00 |
Inside Information Statement
Inside Information / Other news releases
|
English | 121.4 KB | |
| 2025-05-14 18:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 117.5 KB | |
| 2025-05-14 07:30 |
General Meeting Notice
Inside Information / Other news releases
|
English | 71.4 KB | |
| 2025-05-14 07:30 |
General Meeting Notice
Informations privilégiées / Autres communiqués
|
French | 147.0 KB | |
| 2025-05-13 18:00 |
Earnings Release
Informations privilégiées / Autres communiqués
|
French | 131.8 KB | |
| 2025-05-13 18:00 |
Earnings Release
Inside Information / Other news releases
|
English | 118.8 KB | |
| 2025-05-12 07:30 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 140.1 KB | |
| 2025-05-12 07:30 |
Inside Information Statement
Inside Information / Other news releases
|
English | 861.7 KB | |
| 2025-04-28 18:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 958.7 KB | |
| 2025-04-28 18:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 836.1 KB | |
| 2025-04-22 14:35 |
Major Shareholding Notification
Franchissement de seuils et déclaration d'intention
|
French | 115.6 KB | |
| 2025-04-14 18:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 93.6 KB | |
| 2025-04-14 18:00 |
Report Publication Announcement
Informations privilégiées / Autres communiqués
|
French | 139.7 KB | |
| 2025-04-11 15:17 |
Annual Report (ESEF)
Document d’Enregistrement Universel (DEU) 2024
|
French | 16.2 MB | |
| 2025-04-11 12:07 |
Declaration of Voting Results & Voting Rights Announcements
Franchissement de seuils
|
French | 201.6 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-12 | N/A | Other | Sell | 8 | 60.87 EUR |
| 2024-07-11 | N/A | Other | Sell | 57 | 436.14 EUR |
| 2023-12-22 | N/A | Other | Buy | 2,940 | 14,994.00 EUR |
| 2023-12-22 | N/A | Other | Buy | 1,960 | 9,996.00 EUR |
| 2023-09-27 | N/A | Other | Buy | 500 | 3,050.00 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |